Eli Lilly weight loss drug retatrutide clears obesity trial

Key Points:

• Eli Lilly's next-generation obesity drug, retatrutide, achieved significant weight loss in a late-stage Phase 3 trial, with the highest dose leading to an average 28.3% weight loss over 80 weeks, far surpassing placebo results.
• Approximately 45% of patients on retatrutide lost 30% or more of their body weight, and 65% achieved a BMI under 30, indicating substantial efficacy compared to existing treatments like Lilly's Zepbound and Novo Nordisk's Wegovy.
• The drug, targeting three gut hormones (GLP-1, GIP, and glucagon), showed gastrointestinal side effects such as nausea and diarrhea, particularly at higher doses, but safety data were consistent with other GLP-1 medications and no cardiac or liver issues were observed.
• Retatrutide is critical to Lilly's strategy to maintain market dominance in the obesity and diabetes drug sector, projected to be worth $100 billion by the 2030s, with analysts estimating $3.8 billion in sales by 2030.
• Novo Nordisk is developing a competing triple-agonist drug but is several years behind Lilly's retatrutide, highlighting a competitive race in the rapidly growing weight loss and diabetes treatment market.